Guobang Pharma Ltd (SHG:605507) — Market Cap & Net Worth
Market Cap & Net Worth: Guobang Pharma Ltd (605507)
Guobang Pharma Ltd (SHG:605507) has a market capitalization of $1.24 Billion (CN¥8.51 Billion) as of June 23, 2026. Listed on the SHG stock exchange, this China-based company holds position #8128 globally and #1957 in its home market, demonstrating a -5.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guobang Pharma Ltd's stock price CN¥15.22 by its total outstanding shares 558823500 (558.82 Million). Review debt load of Guobang Pharma Ltd to assess the company's total debt and financial obligations.
Guobang Pharma Ltd Market Cap History: 2021 to 2026
Guobang Pharma Ltd's market capitalization history from 2021 to 2026. Data shows change from $2.24 Billion to $1.24 Billion (-19.44% CAGR).
Guobang Pharma Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guobang Pharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.34x
Guobang Pharma Ltd's market cap is 0.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.47x
Guobang Pharma Ltd's market cap is 2.47 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.24 Billion | $4.51 Billion | $706.03 Million | 0.50x | 3.17x |
| 2022 | $2.07 Billion | $5.72 Billion | $920.90 Million | 0.36x | 2.25x |
| 2023 | $1.41 Billion | $5.35 Billion | $612.46 Million | 0.26x | 2.30x |
| 2024 | $1.70 Billion | $5.89 Billion | $781.60 Million | 0.29x | 2.18x |
| 2025 | $2.03 Billion | $6.01 Billion | $820.82 Million | 0.34x | 2.47x |
Competitor Companies of 605507 by Market Capitalization
Companies near Guobang Pharma Ltd in the global market cap rankings as of June 23, 2026.
Key companies related to Guobang Pharma Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Guobang Pharma Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Guobang Pharma Ltd's market cap moved from $2.24 Billion to $ 1.24 Billion, with a yearly change of -19.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.24 Billion | -38.63% |
| 2025 | CN¥2.03 Billion | +19.06% |
| 2024 | CN¥1.70 Billion | +20.74% |
| 2023 | CN¥1.41 Billion | -31.87% |
| 2022 | CN¥2.07 Billion | -7.40% |
| 2021 | CN¥2.24 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Guobang Pharma Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.24 Billion USD |
| MoneyControl | $1.24 Billion USD |
| MarketWatch | $1.24 Billion USD |
| marketcap.company | $1.24 Billion USD |
| Reuters | $1.24 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guobang Pharma Ltd
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives.… Read more